Anti-tumor Effects of Monoclonal Antibody-ricin Conjugates In Vitro and In Vivo

[1]  Y. Masuho,et al.  Ricin A-chain conjugated with monoclonal anti-L1210 antibody , 1983, Cancer Immunology, Immunotherapy.

[2]  L. Miller,et al.  Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. , 1987, Cancer research.

[3]  D. Blakey,et al.  Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. , 1987, Cancer research.

[4]  P. Knowles,et al.  Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue sepharose CL-6B. , 1987, Analytical biochemistry.

[5]  C. Vogel.  Immunoconjugates : antibody conjugates in radioimaging and therapy of cancer , 1987 .

[6]  P. Casellas,et al.  Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. , 1986, Blood.

[7]  P. Casellas,et al.  Determination of sensitivity of fresh leukemia cells to immunotoxins. , 1986, Cancer research.

[8]  B. Foxwell,et al.  Selective uptake of ricin A‐chain by hepatic non‐parenchymal cells in vitro , 1986, FEBS letters.

[9]  W. Ross,et al.  Fate of an antibody-ricin A chain conjugate administered to normal rats. , 1986, Biochemical pharmacology.

[10]  P. Casellas,et al.  Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. , 1986, European journal of biochemistry.

[11]  D. Blakey,et al.  Effect of chemical deglycosylation on the in vivo fate of ricin A-chain. , 1986, Cancer drug delivery.

[12]  R. Zittoun,et al.  Autologous bone marrow transplantation with marrow decontaminated by immunotoxin T 101 in the treatment of leukemia and lymphoma: first clinical observations. , 1985, Cancer treatment reports.

[13]  F. Stirpe,et al.  Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. , 1985, European journal of biochemistry.

[14]  R. Youle,et al.  Ex vivo T cell depletion with immunotoxins in allogeneic bone marrow transplantation: The pilot clinical study for prevention of graft-versus-host disease , 1985 .

[15]  P. Casellas,et al.  Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores. , 1984, The Journal of biological chemistry.

[16]  J. Uhr,et al.  Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain , 1984, The Journal of experimental medicine.

[17]  B. Foxwell,et al.  Blockade of the galactose-binding sites of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates. , 1984, European journal of biochemistry.

[18]  G. Poste,et al.  Receptor-Mediated Targeting of Drugs , 1984, Springer US.

[19]  D. C. Edwards,et al.  Ricin B chain converts a non‐cytotoxic antibody‐ricin A chain conjugate into a potent and specific cytotoxic agent , 1983, FEBS letters.

[20]  Y. Masuho,et al.  Monoclonal anti-MM46 antibody:ricin A chain conjugate: in vitro and in vivo antitumor activity. , 1982, Cancer research.

[21]  D. Mason,et al.  Selective killing of malignant cells in a leukaemic rat bone marrow using an antibody–ricin conjugate , 1982, Nature.

[22]  D. Neville,et al.  Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Pihl,et al.  Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. , 1980, Experimental cell research.

[24]  J. Drews,et al.  The binding of tritiated elongation-factors 1 and 2 to ribosomes from Krebs II mouse ascites-tumore cells. The influence of various antibiotics and toxins. , 1976, European journal of biochemistry.

[25]  P. Kallós.  Progress in Allergy. , 1949 .